Viridian Therapeutics (VRDN) on Monday reported "positive" topline data from the elegrobart REVEAL-1 phase 3 clinical trial in patients with active thyroid eye disease.

Wedbush said the study met its primary endpoint but raised questions on competitive profile. Wedbush cut its price target to $37 from $44 while maintaining its outperform rating.

Shares sank 32%, with an intraday trading volume of over 10.6 million against a daily average of about 1.43 million.

Sysco (SYY) agreed to acquire Jetro Restaurant Depot in a cash-and-stock deal worth about $29.1 billion in enterprise value to enter the Cash & Carry channel.

Shares dropped about 14%, with an intraday trading volume of over 16.3 million, versus a daily average of roughly 3.8 million.

Price: 18.49, Change: -8.90, Percent Change: -32.49